Barclays PLC Phathom Pharmaceuticals, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 76,463 shares of PHAT stock, worth $386,902. This represents 0.0% of its overall portfolio holdings.

Number of Shares

76,463

Previous 57,807 32.27%

Holding current value

$386,902

Previous $1.04 Million 40.52%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$7.45 - $18.94 $138,987 - $353,344	18,656 Added 32.27%	76,463 $621,000
Q3 2024 Nov 15, 2024	BUY	$10.25 - $19.5 $465,370 - $885,339	45,402 Added 366.0%	57,807 $1.04 Million
Q2 2024 Aug 14, 2024	SELL	$8.97 - $12.05 $141,672 - $190,317	-15,794 Reduced 56.01%	12,405 $128,000
Q1 2024 May 15, 2024	SELL	$6.21 - $11.05 $133,347 - $237,276	-21,473 Reduced 43.23%	28,199 $300,000
Q4 2023 Feb 15, 2024	BUY	$6.99 - $10.71 $254,694 - $390,240	36,437 Added 275.31%	49,672 $454,000
Q3 2023 Nov 07, 2023	BUY	$10.26 - $15.7 $24,849 - $38,025	2,422 Added 22.4%	13,235 $137,000
Q2 2023 Aug 03, 2023	SELL	$7.28 - $14.32 $12,470 - $24,530	-1,713 Reduced 13.68%	10,813 $155,000
Q1 2023 May 04, 2023	BUY	$6.19 - $12.36 $22,574 - $45,076	3,647 Added 41.07%	12,526 $89,000
Q4 2022 Feb 13, 2023	BUY	$9.18 - $11.53 $72,549 - $91,121	7,903 Added 809.73%	8,879 $100,000
Q3 2022 Nov 03, 2022	SELL	$6.46 - $12.11 $24,489 - $45,909	-3,791 Reduced 79.53%	976 $11,000
Q2 2022 Aug 12, 2022	SELL	$6.2 - $15.5 $13,640 - $34,100	-2,200 Reduced 31.58%	4,767 $40,000
Q1 2022 May 16, 2022	BUY	$11.55 - $20.06 $80,468 - $139,758	6,967 New	6,967 $94,000

Others Institutions Holding PHAT

# of Institutions

158

Shares Held

68.6M

Call Options Held

52.3K

Put Options Held

635K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $198M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account